Get started
Author

Anna Sergeevna Olshanskaya

Observed names: A. Olshanskaia, A. Olshanskaya, A. S. Ol'shanskaya, A. S. Olshanskaya, A. S. Ol’shanskaya, Anna Olshanskaia, Anna Olshanskaya, Anna S. Olshanskaya, Olshanskaya Anna, А. С. Ольшанская, Ольшанская А.С., Ольшанская Анна Сергеевна
ORCID: 0000-0003-0389-564X
Observed ORCID: 0000-0003-0389-564X
OpenAlex ID: A5036714787
Expression of Receptor Tyrosine Kinases on Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes in Patients with Renal Cell Carcinoma and Healthy Donors
2020 · Ilya Tsimafeyeu, Maria Volkova, et al. · Oncology · 11
Immunochemical expression of fibroblast growth factor and its receptors in primary tumor cells of renal cell carcinoma.
2021 · Maria Volkova, Ilya Tsimafeyeu, et al. · PubMed · 9
A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models
2024 · I. Tsimafeyeu, P. Makhov, et al. · Immuno-Oncology Technology · 7
PDF
Cabozantinib: from studies to clinical practice
2019 · V. В. Matveev, A. S. Olshanskaya, et al. · Cancer Urology · 6
PDF
Expression of the Vascular Endothelial Growth Factor and Its Receptors (vegfr-1 and Vegfr-2) in Primary Tumor Cells in Patients With Renal Cancer
2021 · D. A. Khochenkov, M. I. Volkova, et al. · Siberian Journal of Oncology · 4
PDF
Efficacy and safety of cabozantinib in metastatic renal cell carcinoma patients: Russian multicenter observational study
2023 · M. I. Volkova, A. S. Kalpinskiy, et al. · Cancer Urology · 3
Expression of growth factors and their receptors in the primary renal cell carcinoma: new data and review
2020 · Maria Volkova, Ilya Tsimafeyeu, et al. · Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication · 3
PDF
Changing paradigm of immunooncology in advanced kidney cancer: nivolumab and ipilimumab combination in the first line therapy
2019 · V. B. Matveev, M. I. Volkova, et al. · Cancer Urology · 3
PDF
Toxicity and safety of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell cancer: The Russian phase IV observational study
2024 · Maria I. Volkova, Alexey S. Kalpinskiy, et al. · Journal of Modern Oncology · 2
PDF
Efficacy and safety of lenvatinib and everolimus combination in patients with metastatic renal cell carcinoma progression following targeted antiangiogenic therapy: secondary analysis of data obtained in the Russian multicenter observational study
2021 · M. I. Volkova, A. S. Kalpinskiy, et al. · Cancer Urology · 2
PDF
Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM.
2020 · Maria Volkova, Ahmed Abdelgafur, et al. · Journal of Clinical Oncology · 2
Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM
2019 · M. I. Volkova, A. M. Abdelgafur, et al. · Cancer Urology · 2
PDF
Immunotherapy in urothelial cancer: recent data and perspectives
2017 · M. I. Volkova, Ya. V. Gridneva, et al. · Cancer Urology · 2
Avelumab in combination with axitinib and nivolumab in combination with ipilimumab in the first-line treatment of metastatic renal cell carcinoma: a realworld retrospective cohort study
2025 · I. V. Tsimafeyeu, O. V. Baklanova, et al. · Malignant tumours · 1
PDF
Efficacy of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell carcinoma
2024 · M. I. Volkova, A. S. Kalpinskiy, et al. · Cancer Urology · 1
PDF
Fibrinogen Levels in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: Results of a Multicenter Prospective Trial
2023 · Ilya Tsimafeyeu, Gunel Musaeva, et al. · Kidney Cancer · 1
PDF
Safety and toxicity of cabozantinib monotherapy in patients with advanced renal cell carcinoma: a Russian multicenter observational study
2023 · Maria I. Volkova, Alexey S. Kalpinskiy, et al. · Journal of Modern Oncology · 1
PDF
The Debut of Inflammatory Musculoskeletal Pathology in Patients Receiving Anticancer Therapy with PD-1/PD-L1 Pathway Inhibitors
2022 · A. D. Koltakova, A. M. Lila, et al. · Modern Rheumatology Journal · 1
PDF
1695P Neutralizing anti-FGFR1 antibody as a combined partner of anti-PD-1 antibodies in tumor models
2022 · I. Tsimafeyeu, J. Smith, et al. · Annals of Oncology · 1
PDF
Expression of growth factors and tyrosine kinase receptors in the primary tumor and tumor thrombus cells in patients with renal cell carcinoma
2020 · M. I. Volkova, A. S. Olshanskaya, et al. · Cancer Urology · 1
PDF
Lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: an initial Russian experience
2018 · M. I. Volkova, O. I. Evsyukova, et al. · Cancer Urology · 1
PDF
Is there receptor tyrosine kinases expression on lymphocytes in patients with renal cell carcinoma? First-in-human study
2017 · D. Khochenkov, M. Volkova, et al. · Annals of Oncology · 1
Real-world efficacy and safety of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: Updated data from a Russian observational study
2025 · Maria I. Volkova, Alexey S. Kalpinskiy, et al. · Journal of Modern Oncology
PDF
Expression of Platelet-Derived Growth Factor Alpha and Beta Receptors in Primary Tumor Cells of Patients with Renal Cell Carcinoma
2025 · Maria Volkova, Dmitry Khochenkov, et al. · Urology Research and Practice
1073P Overcoming resistance to immunotherapy with FGFR inhibition in GU cancer models
2023 · I. Tsimafeyeu, Q. Wang, et al. · Annals of Oncology
PDF
Works count: 41
Citation count: 65
H-index: 4
I10-index: 1
Year
Topic
Type